Suppr超能文献

采用免疫亲和层析结合 SRM 分析血清总 PSA 和游离 PSA:与临床免疫测定试验的相关性。

Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.

机构信息

Biological Sciences Division, Pacific Northwest National Laboratory, United States.

出版信息

J Proteomics. 2012 Aug 3;75(15):4747-57. doi: 10.1016/j.jprot.2012.01.035. Epub 2012 Feb 13.

Abstract

Recently, selected reaction monitoring mass spectrometry (SRM-MS) has been more frequently applied to measure low abundance biomarker candidates in tissues and biofluids, owing to its high sensitivity and specificity, simplicity of assay configuration, and exceptional multiplexing capability. In this study, we report for the first time the development of immunoaffinity depletion-based workflows and SRM-MS assays that enable sensitive and accurate quantification of total and free prostate-specific antigen (PSA) in serum without the requirement for specific PSA antibodies. Low ng/mL level detection of both total and free PSA was consistently achieved in both PSA-spiked female serum samples and actual patient serum samples. Moreover, comparison of the results obtained when SRM PSA assays and conventional immunoassays were applied to the same samples showed good correlation in several independent clinical serum sample sets. These results demonstrate that the workflows and SRM assays developed here provide an attractive alternative for reliably measuring candidate biomarkers in human blood, without the need to develop affinity reagents. Furthermore, the simultaneous measurement of multiple biomarkers, including the free and bound forms of PSA, can be performed in a single multiplexed analysis using high-resolution liquid chromatographic separation coupled with SRM-MS. This article is part of a Special Issue entitled: Translational Proteomics.

摘要

最近,由于其高灵敏度和特异性、检测配置的简单性以及出色的多重检测能力,选择反应监测质谱(SRM-MS)在测量组织和生物体液中的低丰度生物标志物候选物方面的应用越来越频繁。在本研究中,我们首次报道了免疫亲和 depletion 为基础的工作流程和 SRM-MS 检测方法的开发,这些方法可在不使用特定 PSA 抗体的情况下,灵敏且准确地定量血清中的总 PSA 和游离 PSA。在 PSA 浓度为 ng/mL 的女性血清样本和实际患者血清样本中,均能始终实现总 PSA 和游离 PSA 的低 ng/mL 检测。此外,当将 SRM PSA 检测方法和常规免疫检测方法应用于相同的样本时,对几个独立的临床血清样本集进行比较,结果显示出良好的相关性。这些结果表明,这里开发的工作流程和 SRM 检测方法为可靠地测量人类血液中的候选生物标志物提供了一种有吸引力的替代方法,而无需开发亲和试剂。此外,还可以使用高分辨率液相色谱分离与 SRM-MS 相结合,在单个多重分析中同时测量多个生物标志物,包括 PSA 的游离和结合形式。本文是一个特刊的一部分,特刊主题为:转化蛋白质组学。

相似文献

1
Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.
J Proteomics. 2012 Aug 3;75(15):4747-57. doi: 10.1016/j.jprot.2012.01.035. Epub 2012 Feb 13.
2
Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion.
J Proteome Res. 2013 Jul 5;12(7):3353-61. doi: 10.1021/pr400178v. Epub 2013 Jun 13.
5
Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues.
Anal Chem. 2017 Sep 5;89(17):9139-9146. doi: 10.1021/acs.analchem.7b01878. Epub 2017 Aug 11.
7
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15395-400. doi: 10.1073/pnas.1204366109. Epub 2012 Sep 4.

引用本文的文献

1
Multiplexed quantitative proteomics in prostate cancer biomarker development.
Adv Cancer Res. 2024;161:31-69. doi: 10.1016/bs.acr.2024.04.003. Epub 2024 Apr 25.
2
Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression.
Cancers (Basel). 2020 May 17;12(5):1268. doi: 10.3390/cancers12051268.
4
The age-specific reference intervals for tPSA, fPSA, and %fPSA in healthy Han ethnic male.
J Clin Lab Anal. 2017 Jul;31(4). doi: 10.1002/jcla.22062. Epub 2016 Sep 20.
5
Advances in targeted proteomics and applications to biomedical research.
Proteomics. 2016 Aug;16(15-16):2160-82. doi: 10.1002/pmic.201500449.
6
Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:57-68. doi: 10.1016/j.jchromb.2016.01.015. Epub 2016 Jan 12.
7
The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification.
Expert Rev Proteomics. 2016;13(1):99-114. doi: 10.1586/14789450.2016.1122529. Epub 2015 Dec 19.
8
Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma.
PLoS One. 2015 Sep 1;10(9):e0136911. doi: 10.1371/journal.pone.0136911. eCollection 2015.
10
Expediting SRM assay development for large-scale targeted proteomics experiments.
J Proteome Res. 2014 Oct 3;13(10):4479-87. doi: 10.1021/pr500500d. Epub 2014 Sep 4.

本文引用的文献

1
Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7.
2
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.
3
Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.
Nat Rev Clin Oncol. 2011 Mar;8(3):142-50. doi: 10.1038/nrclinonc.2010.220.
5
Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma.
J Natl Cancer Inst. 2010 Sep 8;102(17):1299-301. doi: 10.1093/jnci/djq313. Epub 2010 Aug 19.
6
Antibody-based detection of ERG rearrangement-positive prostate cancer.
Neoplasia. 2010 Jul;12(7):590-8. doi: 10.1593/neo.10726.
8
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.
Bioinformatics. 2010 Apr 1;26(7):966-8. doi: 10.1093/bioinformatics/btq054. Epub 2010 Feb 9.
9
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers.
Expert Opin Med Diagn. 2009 Nov 1;3(6):597-605. doi: 10.1517/17530050903266830.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验